Last €46.74 EUR
Change Today +0.69 / 1.49%
Volume 120.0
MYL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Munich
As of 1:35 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

mylan inc (MYL) Snapshot

Open
€46.06
Previous Close
€46.05
Day High
€46.74
Day Low
€45.25
52 Week High
11/28/14 - €47.80
52 Week Low
01/7/14 - €30.77
Market Cap
17.5B
Average Volume 10 Days
507.7
EPS TTM
--
Shares Outstanding
374.3M
EX-Date
07/17/07
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MYLAN INC (MYL)

mylan inc (MYL) Details

Mylan Inc., a pharmaceutical company, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch form, as well as active pharmaceutical ingredients (APIs). This segment is also involved in developing APIs with non-infringing processes to partner with manufacturers; and the manufacture and sale of injectable products in the therapeutic areas of antineoplastics, anti-infectives, anesthesia/pain management, and cardiovascular. In addition, it produces finished dosage form (FDF) products for the antiretroviral (ARV) market and non-ARV FDF products that are marketed to third parties. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable and nebulized products comprising EpiPen Auto-Injector for the treatment of severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. It also offers ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. to develop, manufacture, distribute and market generic drugs in Japan. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

20,000 Employees
Last Reported Date: 02/27/14
Founded in 1961

mylan inc (MYL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.1M
President, Director and Member of Science & T...
Total Annual Compensation: $840.4K
Executive Chairman and Chairman of Executive ...
Total Annual Compensation: $1.4M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $650.0K
Compensation as of Fiscal Year 2013.

mylan inc (MYL) Key Developments

Mylan Inc. Launches Generic Robaxin Injection

Mylan Inc. announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials. This product is the generic version of Hikma Maple Ltd.'s Robaxin. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Methocarbamol Injection, which is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. Mylan's immediate shipment of this product supports the growth of the company's portfolio of more than 100 injectable products in the U.S. Methocarbamol Injection USP, 100 mg/mL, had U.S. sales of approximately $15.1 million for the 12 months ending September 30, 2014.

Mylan Inc. Launches First Generic Version of Orapred ODT

Mylan Inc. announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions.

Mylan Launches Generic Version of Pfizer's Celebrex

Mylan has launched of its generic version of Pfizer's (PFE) Celebrex capsules in the U.S. The drug is indicated for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYL:GR €46.74 EUR +0.69

MYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Omnicare Inc $73.59 USD +0.49
Perrigo Co PLC $168.14 USD +3.29
UCB SA €65.79 EUR +0.77
WW Grainger Inc $257.81 USD +5.58
WESCO International Inc $76.99 USD +0.62
View Industry Companies
 

Industry Analysis

MYL

Industry Average

Valuation MYL Industry Range
Price/Earnings 24.8x
Price/Sales 2.9x
Price/Book 6.4x
Price/Cash Flow 23.4x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYLAN INC, please visit www.mylan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.